Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.86 |
| ▸ | CNR1 | P21554 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664503 | 0.93 | CNR2 (0.86) | CNR2CNR1ALDH1A1 | |
| SCHEMBL12862694 | 0.93 | CNR2 (0.86) | CNR2CNR1ALDH1A1 | |
| SCHEMBL3656878 | 0.88 | CNR2 (0.86) | CNR2CNR1ALDH1A1 | |
| SCHEMBL14201250 | 0.87 | CNR2 (0.85) | CNR2CNR1ALDH1A1 | |
| SCHEMBL4910778 | 0.85 | CNR2 (0.77) | CNR2CNR1ALDH1A1 | |
| SCHEMBL4410778 | 0.85 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL30187039 | 0.84 | CNR2 (1.00) | CNR2CNR1ALDH1A1 | |
| SCHEMBL3684662 | 0.84 | CNR2 (1.00) | CNR2CNR1ALDH1A1 | |
| SCHEMBL2774135 | 0.78 | CNR2 (0.93) | CNR2CNR1 | |
| SCHEMBL5903605 | 0.77 | CNR2 (0.76) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | NOGRA PHARMA LIMITED (IE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | NOGRA PHARMA LIMITED (IE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | NOGRA PHARMA LIMITED (IE) | 2011-02-17 | — | — | US | disclosed |
| EP-2222287-A2 | MULTITARGET COMPOUNDS ACTIVE AT A PPAR AND CANNABINOID RECEPTOR | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080821-A2 | RECEPTOR TARGETING LIGANDS | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | PPARA, PPARG, PPARD | CNR2 5/4885CNR1 4/4885ALDH1A1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.